



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Lal Attorney Docket No.: SNUS121479
Application No.: 10/622,007 Group Art Unit: 1614
Filed: July 16, 2003 Examiner: --
Title: PLATINUM COMPOUNDS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

March 31, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the listed other information are enclosed for the Examiner's use.
2. X Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}

George E. Benzoni, Ph.D.
Registration No. 37,919
Direct Dial No. 206.695.1755

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:

GER:md

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



INFORMATION CITED BY APPLICANT(S) THAT MAY BE MATERIAL TO THE
PROSECUTION OF THE SUBJECT APPLICATION

Applicant: M. Lal Attorney Docket No. SNUS121479
Application No.: 10/622,007 Group Art Unit: 1614
Filed: July 16, 2003 Examiner: --
Title: PLATINUM COMPOUNDS

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	Document No.	Kind Code	Date (mm/dd/yyyy)	Name
	U7	4,140,707	A	02/20/1979	Cleare et al.
	U8	4,177,263	A	12/04/1979	Rosenberg et al.
	U9	6,011,166	A	01/04/2000	Valsecchi et al.

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	Document No.	Kind Code	Publication Date (mm/dd/yyyy)	Country	English Abstract Provided	Translation Provided
NONE							

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	Cite No.	
	O8	Leonetti, C., et al., "α-Tocherol Protects Against Cisplatin-Induced Toxicity Without Interfering With Antitumor Efficacy," <i>Int. J. Cancer</i> 104(2):243,250, 2003.
	O9	Manzotti, C., et al., "BBR 3464: A Novel Triplatinum Complex, Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin," <i>Clinical Cancer Res.</i> 6:2626-2634, July 2000.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- _____ O10 Martin-Ramos, J.D., et al., "Copper(II) and Nickel(II) Chelated With Dihydrogen Trans-1,2-Diaminocyclohexane-N,N,N',N'-Tetraacetate(2-) Ion ($\text{H}_2\text{CDTA}^{2-}$). Synthesis, XRD Structure and Properties of $[\text{Cu}(\text{H}_2\text{CDTA})] \cdot \text{H}_2\text{O}$ and $[\text{Ni}(\text{H}_2\text{CDTA})(\text{H}_2\text{O})] \cdot 4\text{H}_2\text{O}$ ", *Polyhedron* 15(3) 439-446, 1996.
- _____ O11 Pace, A., et al., "Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy," *J. Clin. Oncol.* 21(5):927-391 March 2003.

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GER:md

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100